Sol-Gel Technologies (SLGL) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sol-Gel Technologies has struck six exclusive licensing deals to market their dermatology products TWYNEO and EPSOLAY in most European countries and South Africa, with financials involving upfront and milestone payments up to low 7-digit USD figures, alongside future sales royalties. These agreements, which include commitments to minimum annual sales, build on Sol-Gel’s existing partnerships in the US, Canada, and China, showcasing the growing global confidence in their products. The company continues to advance its clinical trials for other potential treatments, further strengthening its competitive position in the dermatology pharmaceutical market.
For further insights into SLGL stock, check out TipRanks’ Stock Analysis page.
